Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Global Over the Counter Drugs Market (2020-2025) by Mode of Intake, Product, End-user Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Over the Counter Drugs Market is estimated to be USD 361 Bn in 2020 and is expected to reach USD 539 Bn by 2025, growing at a CAGR of 8.35%.
Increasing awareness regarding the personalized medicine for treating minor ailments and introduction of treatment protocols by healthcare payers and also rapidly increasing chronic diseases are some of the major driving factors making remarkable new drug development and impact positively the expansion of the over the counter (OTC) drugs market. In fact, the proper drug for the proper patient at the proper time is the mantra of personalized medicine.
The Global over the Counter Drugs Market is segmented further based on Mode of Intake, Product, End-user and Geography.
By Mode of Intake, the market is classified as Topical, Oral and Parenteral.
By Product, the market is classified as Analgesics, Weight Loss/Dietary Products, Gastrointestinal Products, Cold, Cough and Flu Products, Mineral and Vitamin Supplements, Skin Products, Ophthalmic Products, Sleeping Aids and Dermatology Products.
By End User, the market is classified as Retail Pharmacies, Online Pharmacies, Hospital and Pharmacies.
By Geography, North America is projected to lead the market.
1. In July 2020, Stada AG, a Germany-based pharmaceutical company, announced about acquisition of 15 of deep-rooted OTC brands from GlaxoSmithKline in Europe. The acquisition will strengthen the company's portfolio and presence in the consumer health business.
2. In January 2018, Nuvo Pharmaceuticals, Inc. acquired ex-U.S. product and existing royalty streams for 'Resultz', an OTC treatment for head lice from Piedmont Pharmaceuticals LLC.
3. Takeda Pharmaceuticals in March 2016, started overseas sales of OTC brand - Alinamin in Vietnam, India, Hong-Kong, and China.
Some of the companies covered in this report are AbbVie Inc., Alacer Corp, Bausch & Lomb, Bayer Healthcare AG, Boehringer Ingelheim GmbH, Cipla Ltd., Dr. Reddy's Laboratories, GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., The Colgate-Palmolive Company., etc.
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
The report offers a comprehensive evaluation of the Global Over the Counter Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
The report also contains the competitive analysis using the Competitive Quadrant, the analyst's proprietary competitive positioning tool.
A complete analysis of the market, including parent industry
Important market dynamics and trends
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
4 Market Overview
4.2 Market Dynamics
126.96.36.199 Improvement in lifestyle and age related diseases
188.8.131.52 The rise in self-directed consumer
184.108.40.206 Growing awareness regarding general health concerns and advancements in healthcare industry
220.127.116.11 Stringent regulatory policies by governing bodies
18.104.22.168 Lack of seamless reclassification of drugs from prescription medicines to over the counter drugs
22.214.171.124 Increasing R&D expenditure and funding from the public & private sector
126.96.36.199 Firms are seeking portfolio expansion strategies to cater to the growing demand for over-the-counter drugs.
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Over the Counter Drugs Market, By Mode of Intake
7 Global Over the Counter Drugs Market, By Product
7.2 Weight Loss/Dietary Products
7.3 Gastrointestinal Products
7.4 Cold, Cough and Flu Products
7.5 Mineral and Vitamin Supplements
7.6 Skin Products
7.7 Ophthalmic Products
7.8 Sleeping Aids
7.9 Dermatology Products
8 Global Over the Counter Drugs Market, By End User
8.2 Retail Pharmacies
8.3 Online Pharmacies
8.4 Hospital Pharmacies
9 Global Over the Counter Drugs Market, By Geography
9.2 North America
9.3 South America
9.4.6 Rest of Europe
9.5.6 South Korea
9.5.9 Rest of APAC
9.6 Rest of the World
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
9.6.5 Latin America
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreement, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Funding
11 Company Profiles
11.1 AbbVie Inc.
11.2 Alacer Corp.
11.3 Alcon Inc.
11.4 Alfresa Pharma Corporation
11.5 Alkalon A/S
11.6 Alkem Laboratories Limited
11.7 Allergan, Plc.
11.8 Alliance Healthcare
11.9 AstraZeneca plc.
11.10 Bausch & Lomb
11.11 Bayer Healthcare AG
11.12 Boehringer Ingelheim GmbH
11.13 Cipla Ltd.
11.14 Dr. Reddy's Laboratories
11.15 Gilead Sciences
11.16 GlaxoSmithKline Plc.
11.17 Glenmark Pharmaceuticals Ltd.
11.18 Johnson and Johnson Inc.
11.19 Merck & Co. Inc.
11.20 Novartis International AG
11.21 Pfizer Inc.
11.22 Reckitt Benckiser Group Plc
11.23 Roche Holding AG
11.24 Sanofi S.A
11.25 Sun Pharmaceutical Industries Ltd.
11.26 Teva Pharmaceutical Industries Ltd.
11.27 The Colgate-Palmolive Company
For more information about this report visit https://www.researchandmarkets.com/r/7i6lpg
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900